Femtech

Inc.’s 2024 Female Founders list highlights why female founders are always a good bet

Retrieved on: 
Tuesday, April 9, 2024
BCG, Genomics, AngelList, Organization, Growth, Female, Environment, Rihanna, Research, University, Entrepreneurship, Private sector, Doctor of Philosophy, Biology, Woman, Male, STEM, Molecular biology, Femtech, UW, Hedera, Nursing

Elizabeth Ruzzo, CEO and founder of adyn, was recognized by Inc. in this year’s Female Founders list.

Key Points: 
  • Elizabeth Ruzzo, CEO and founder of adyn, was recognized by Inc. in this year’s Female Founders list.
  • The female founders on this year’s list are a testament to what triumph over adversity looks like.
  • “One thing I bet all founders on this list share is an abundance of grit and determination.
  • Despite years of evidence demonstrating that female founders are a good bet, the fundraising environment remains bleak.

ELVIE PUTS MATERNAL SUPPORT UNDER A MICROSCOPE WITH NEW REPORT

Retrieved on: 
Tuesday, April 9, 2024
Mother, BUT, Health, Face, Woman, Lactation, Partnership, Education, Periodic function, Mental health, Research, Sleep, The Motherload, Femtech, Breastfeeding, Policy, Prenatal care, Postpartum period, Pregnancy, Thought, Biology, Loneliness, Animation, Pelvic floor, Baby Blues, Family, Marketing, Frustration, Birth control

NEW YORK, April 9, 2024 /PRNewswire/ -- Today, Elvie, the disruptive global FemTech health and wellness brand, releases "The Motherload: The weight of limited postpartum support," their first-ever report, in partnership with Mother.ly, putting the state of maternal health under the microscope. The study of over 1,000 women with children has uncovered a trio of serious pregnancy and postpartum challenges that mothers currently face. 

Key Points: 
  • As a female-founded and female-grounded company, Elvie has worked tirelessly to empower women through radical female-first technology that harnesses their incredible biology.
  • "With this new research, we're demonstrating something those mothers already know: postpartum care in the US is simply not good enough."
  • Only 28% say they had good mental health during the postpartum period, but only 31% had professional mental health support.
  • While mothers understand that postpartum challenges are guaranteed, they're often complicated by a lack of strong structural support and poor paid maternity leave policies.

Cosm Medical Achieves FDA Clearance for Gynethotics™ Pessaries, Pioneering the future of personalized pelvic care

Retrieved on: 
Thursday, March 14, 2024
Research, Medical Devices, Medical Supplies, FDA, Clinical Trials, Other Health, Biotechnology, Health, Science, Other Science, Pessary, Medicine, Partnership, Patient, Journal, Incontinence, University, Femtech, Health Canada, Trial of the century, Woman, Gynaecology, Prolapse, Birth control

Cosm Medical proudly announces FDA clearance for Gynethotics™ Pessaries, marking it as the first personalized pessary available to patients.

Key Points: 
  • Cosm Medical proudly announces FDA clearance for Gynethotics™ Pessaries, marking it as the first personalized pessary available to patients.
  • This milestone follows a recent Health Canada clearance and marks a significant advancement in pelvic care, emphasizing Cosm’s commitment to enhancing patient outcomes and revolutionizing treatment options for women worldwide.
  • Gynethotics™ are the first pessary to be FDA cleared in about 5 years with almost 10 million pessary configurations that clinicians can conveniently order online.
  • “Our vision is to become the world leader in precision gynecological devices for unique bodies and needs.” said Derek Sham, Founder & CEO of Cosm Medical.

Zcube Launches the 2024 Edition of Open Accelerator, an International Acceleration Program Aimed at Life Sciences Startups with Focus on Women's Health and Femtech

Retrieved on: 
Wednesday, February 28, 2024
Health, Venture Capital, Neurology, Finance, Consumer, Other Health, Professional Services, Oncology, Other Science, Mental Health, General Health, Science, Women, Cardiology, Cervical cancer, Mental health, Call, Investment, Physician, Partnership, Femtech, Venture capital, Gynaecology, Endocrinology, Ecosystem, SAFE, Patient, Intellectual property, Diagnosis, HTH, Community, Wi-Fi Direct, Gastroenterology, Pharmaceutical industry

Zcube - Zambon Research Venture announces the fifth edition of Open Accelerator, the international acceleration program for high-potential innovative startups in the field of life sciences.

Key Points: 
  • Zcube - Zambon Research Venture announces the fifth edition of Open Accelerator, the international acceleration program for high-potential innovative startups in the field of life sciences.
  • Starting this year, the program will focus on the femtech sector and will feature a new format.
  • The targeted therapeutic areas include gynecology, cardiovascular health, oncology, sexual health, endocrinology, gastroenterology, nutrition, autoimmune disorders, mental health, neurology, reproductive health, and more.
  • The Call for application will open on Friday, March 8, 2024, on the International Women's Day, and will remain open until June 16.

The State of Feeding Survey Reveals Only 40% of New Moms Meet Personal Baby Feeding Expectations, Highlighting an Alarming Gap in Baby Feeding Education and Support

Retrieved on: 
Tuesday, March 5, 2024
SAN, Workplace, Education, Culture, Parent, Pregnancy, Entrepreneurship, Motherboard, Lactation, Breast, Parental leave, Health, Stigma, Parenting, Report, Mother, Infant, Federal, Combo, CDC, Femtech, Partnership, Birth control

SAN FRANCISCO and ITHACA, N.Y., March 5, 2024 /PRNewswire/ -- In a step towards empowering parents' diverse feeding journeys, Willow Innovations, Inc. (Willow), the leading FemTech brand changing how moms breastfeed; Bobbie, the mom-founded pediatric nutrition company; and SimpliFed, a digital lactation consultant network democratizing feeding support, released the findings from their inaugural State of Feeding Survey and Report. These findings are the culmination of a rare partnership that closes the divide within the baby-feeding industry and marks a significant stride in creating a holistic and inclusive approach to support mothers. The State of Feeding survey data underscores the feeding realities of new moms to redefine expectations and allow parents to embrace their unique journeys on their terms.

Key Points: 
  • The State of Feeding survey data underscores the feeding realities of new moms to redefine expectations and allow parents to embrace their unique journeys on their terms.
  • According to the State of Feeding survey, nearly 100% of prepartum and postpartum moms had a plan for how they would feed their babies.
  • 11% of moms intended for a combination of feeding (also known as "Combo Feeding") with breastfeeding, pumping, and formula feeding; however, 65% were combination feeding.
  • Moms who formula feed or pump are less likely to receive support and education, despite the majority of moms are combination feeding.

Mira Introduces First Nationwide Sex Hormones Awareness Week to Close the Knowledge Gap About Female Hormones

Retrieved on: 
Monday, February 19, 2024
SAN, Collection, Woman, Menstrual cycle, Hormone, LH, Female, Femtech, Society, Health, Attention, Women's health, Diagnosis, Menopause, Public, Research, Beginners, Birth control

SAN FRANCISCO, Feb. 19, 2024 /PRNewswire/ -- Mira, a hormonal health company providing integrative care and hormonal testing for women, announced the first nationwide Sex Hormones Awareness Week, set to take place from February 18th to February 24th, 2024. With this initiative, Mira seeks to educate people about their sex hormones so that they can make informed decisions about their health.

Key Points: 
  • With this initiative, Mira seeks to educate people about their sex hormones so that they can make informed decisions about their health.
  • This annual initiative is set to raise public awareness and bridge the gap about female hormonal health.
  • In light of Sex Hormones Awareness Week, the company released a study on how sex hormones affect mood and well-being .
  • For more information about Sex Hormones Awareness Week, visit the link https://www.miracare.com/awareness-week/ .

Introducing Femtech Canada - A New Era in Women's Health Innovation

Retrieved on: 
Wednesday, January 17, 2024
Woman, Sun Life Financial, Shoppers Drug Mart, BLG, Health, Advertising, Female, Ecosystem, Growth, Femtech, Nursing

TORONTO, Jan. 17, 2024 /CNW/ - Femtech Canada , a women's health network initiative operated by Innovation Factory , celebrated its official launch today at a gathering in Toronto, Ontario.

Key Points: 
  • TORONTO, Jan. 17, 2024 /CNW/ - Femtech Canada , a women's health network initiative operated by Innovation Factory , celebrated its official launch today at a gathering in Toronto, Ontario.
  • The launch of Femtech Canada signals a milestone for women's health technology and innovation.
  • Femtech Canada is proudly backed by an advisory board of venture capital members including, Esplanade Ventures, Amplify Capital and Wittington Ventures; femtech companies including Future Fertility and Hyivy Health, and the business accelerator, Innovation Factory.
  • Femtech Canada exists to advance the recognition and resourcing of women's health and wellness companies.

PherDal, the First and Only Sterile At-Home Insemination Kit, Awarded FDA Clearance; Now Accepting Pre-Orders

Retrieved on: 
Tuesday, January 16, 2024
Fertility, Infertility, Science, Insemination, LSI, Kit, Genomics, Conference, IVI, Femtech, FDA

DIXON, Ill., Jan. 16, 2024 /PRNewswire-PRWeb/ -- PherDal Fertility Science, Inc., creators of the first and only sterile, at-home insemination kit, is now accepting pre-orders of its intravaginal insemination (IVI) device, following FDA class II clearance. Rooted in science, the PherDal Kit is the first and only to combine the sterile environment of the fertility clinic with the at-home capabilities of insemination.

Key Points: 
  • Rooted in science, the PherDal Kit is the first and only to combine the sterile environment of the fertility clinic with the at-home capabilities of insemination.
  • Rooted in science, the PherDal Kit is the first and only to combine the sterile environment of the fertility clinic with the at-home capabilities of insemination.
  • Each PherDal Kit includes three (3) sterile syringes and three (3) sterile collection cups to make at-home insemination as sterile, safe and accessible as possible.
  • My husband, a mechanical engineer, and I invented the PherDal Kit, which successfully conceived our daughter with the second use.

Stephanie Schull, PhD, CEO of Kegelbell, acknowledged as a trailblazing leader in women's health and FemTech for two consecutive years

Retrieved on: 
Wednesday, December 20, 2023
Doctor, Women's health, Kate Ryder, Woman, Ferring Pharmaceuticals, FDA, Health, Doctor of Philosophy, Femtech, Creativity

MESA, Ariz., Dec. 20, 2023 /PRNewswire-PRWeb/ -- Stephanie Schull, PhD, the visionary CEO of Kegelbell, has been honored for her exceptional leadership and innovation in the Women's Health and FemTech sectors for the second consecutive year. Recognized among the top 200 Trailblazing Leaders in Women's Health and FemTech for both 2022 and 2023, Stephanie Schull stands out as one of only 60 leaders to achieve this remarkable distinction two years in a row.

Key Points: 
  • "It is an honor to be recognized alongside such accomplished and dedicated leaders in Women's Health and FemTech.
  • At Kegelbell, we remain committed to pushing boundaries and developing solutions that positively impact the lives and health of women globally."
  • The prestigious list, compiled and documented by industry experts Anja Streicher and Marija Butkovic, features influential figures who have significantly contributed to advancing women's health and FemTech.
  • Stephanie Schull's inclusion on the list for two consecutive years underscores her sustained excellence and leadership in the industry.

Femovate Announces 30 New Early-Stage Femtech Startups for Its 2024 UX Design Sponsorship Program

Retrieved on: 
Wednesday, December 13, 2023
Woman, Pelvic floor, Cervical cancer, Chorionic villi, Patient, Research, Ovulation, Infertility, Radiology, Diagnosis, Growth, Lymphedema, Safety, Fertility, Health, MRI, Parent, Femtech, Physician, AI, Face, Endometriosis, Risk, Bleeding, Insurance, IVF, Artificial intelligence, Rehabilitation, Education, Dares Phrygius, Black, Clue, Breast cancer, Pregnancy, FDA, McKinsey & Company, Bias, GFF, Pharmaceutical industry, Medical imaging, Medical device, Birth control, Mobile phone, UX, Ivan Guidea, Mammography

AUSTIN, Texas, Dec. 13, 2023 /PRNewswire-PRWeb/ -- Guidea, an award-winning, women-led UX design agency, today announced 30 new early-stage femtech companies for its 2024 UX design sponsorship program, Femovate, selected from 130 applications across six continents. Launched by Guidea in 2022, the Femovate program has invested more than $1 million in femtech innovation through its UX design sponsorship program, and elevates promising femtech startups by giving them the same kind of services that Guidea provides to the top Fortune 100 companies.

Key Points: 
  • Launched in 2022 by Guidea, an award-winning UX design agency, Femovate helps femtech startups overcome funding inequalities, along with massive scientific and clinical data gaps through its $1 million femtech innovation sponsorship program
    AUSTIN, Texas, Dec. 13, 2023 /PRNewswire-PRWeb/ -- Guidea , an award-winning, women-led UX design agency, today announced 30 new early-stage femtech companies for its 2024 UX design sponsorship program, Femovate , selected from 130 applications across six continents.
  • Launched by Guidea in 2022, the Femovate program has invested more than $1 million in femtech innovation through its UX design sponsorship program, and elevates promising femtech startups by giving them the same kind of services that Guidea provides to the top Fortune 100 companies.
  • The 30 companies selected for the 2024 Femovate program include:
    Deeplook Medical : Revolutionizing radiology for cancer screening, diagnosis, and treatment, with their FDA-approved, patent-protected software.
  • "I'm impressed with the caliber of the femtech companies I've been part of selecting for the 2024 Femovate cohort and the practical support they receive from Femovate."